Last updated: February 15, 2026
What Is the Market Status for NDC 00378-9124?
NDC 00378-9124 corresponds to Ibrutinib (Imbruvica), a targeted therapy indicated primarily for various hematologic malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström's macroglobulinemia.
Imbruvica has established itself as a key drug within its therapeutic area. Its patent protections and exclusivity periods have influenced market dynamics. As of late 2022, generic versions have yet to significantly enter the market, though patent expirations are approaching or have occurred in some regions.
How Large Is the Current Market for Ibrutinib?
Market data from IQVIA indicates U.S. sales of Ibrutinib reached approximately $4.5 billion in 2022, with growth driven by increasing adoption across indications and expanded approvals. Globally, the pharmaceutical market for Ibrutinib is estimated to exceed $6 billion in 2022, considering Europe, Asia-Pacific, and other territories.
Major factors influencing market size include:
- Indication Expansion: Approval for previously off-label or investigational uses enhances revenue potential.
- Line of Therapy: First-line treatment adoption increases volume.
- Pricing Strategies: Variations exist due to patent exclusivity, reimbursement policies, and negotiated prices.
What Are the Price Trends and Projections for Ibrutinib?
Current Pricing Landscape
In the U.S., wholesale acquisition costs (WAC) for Ibrutinib are approximately $7,000 to $9,000 per month per patient. Patient out-of-pocket costs vary with insurance coverage but generally remain significant.
- Average annual treatment cost: $84,000 to $108,000.
- Pricing during exclusivity: Stable, with slight annual increases aligned with inflation and market conditions.
Post-Patent and Generic Entry Outlook
The key patent related to Ibrutinib was set to expire in 2027 [1], with patent protections in some jurisdictions expiring earlier or later based on legal challenges. Once generics enter, direct competition should drive prices downward.
- Expected generic entry: 2026-2027, subject to regulatory and patent litigation timelines.
- Projected price decrease upon generic entry: 40%-60%, based on historical data from other oncology drugs.
Forecasting Future Prices
Assuming a generic market entry in 2027:
| Year |
Estimated Average Monthly Price |
Expected Price Decrease |
Comments |
| 2023 |
$8,000 |
— |
Peak brand pricing, limited generic options |
| 2024 |
$7,700 |
— |
Slight discounts, limited competition |
| 2025 |
$7,200 |
— |
Further price stabilization |
| 2026 |
$6,700 |
— |
Approaching patent expiry, generics emerging |
| 2027+ |
$3,000 - $4,000 |
50-60% |
Generic entry, increased competition |
Key Factors Influencing Future Prices
- Regulatory delays or litigation could push generic entry further.
- Market uptake of biosimilars or alternative therapies may pressure prices.
- Reimbursement policies in different regions impact real-world prices.
How Do Competitors and Alternative Treatments Influence the Market?
- Bruton's tyrosine kinase (BTK) inhibitors: Acalabrutinib (Calquence) and zanubrutinib (Brukinsa) compete within the same class, potentially limiting price growth.
- Chemoimmunotherapy and CAR-T therapies: Offer alternatives in certain indications, influencing demand and market share.
- Biosimilar development: Some competitors are developing biosimilars, which could further depress prices.
What Are the Regulatory and Patent Challenges?
- Patent challenges in the U.S. and Europe threaten to reduce exclusivity early.
- Patent extensions or new formulations might delay generic entry.
- Regulatory delays due to safety or efficacy concerns could impact pricing timelines.
Actionable Insights
- Investors should monitor patent litigation timelines and jurisdiction-specific patent statuses.
- R&D entities interested in biosimilars or new BTK inhibitors should evaluate the remaining market differentiation opportunities.
- Market entrants might gain an advantage by entering early in regions where patent expiration is imminent.
Key Takeaways
- Ibrutinib's U.S. market reached approximately $4.5 billion in 2022.
- Current monthly prices are around $7,000–$9,000 per patient.
- Patent expiration is expected around 2027, with significant price reductions likely post-expiration.
- Competition with existing BTK inhibitors and emerging therapies influences ongoing market growth.
- Patent and regulatory developments are critical to future pricing and market share.
FAQs
1. When will generic versions of Ibrutinib likely enter the market?
Patent expiries are projected around 2027, with generic entry possibly occurring within 1-2 years following, depending on legal and regulatory factors.
2. How much will prices drop after generic entry?
Historical trends suggest a 50-60% reduction in drug prices with generic competition.
3. Are there any approved biosimilars for Ibrutinib?
Currently, no biosimilars have been approved; biosimilar development is in progress in some regions.
4. What are the key competitors to Ibrutinib?
Other BTK inhibitors like acalabrutinib and zanubrutinib serve as alternatives within the same therapeutic class.
5. How will new indications influence market size?
New approvals for additional hematologic conditions could expand the total addressable market considerably.
Citations
[1] U.S. Patent and Trademark Office, Patent Expiration Data, 2022.
